Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 8,305 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the transaction, the insider now owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Greg Keenan also recently made the following trade(s):

• On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total value of $97,912.00.

Aurinia Pharmaceuticals Trading Down 0.5 %

Shares of AUPH traded down $0.04 during trading hours on Friday, hitting $8.15. 1,152,887 shares of the stock traded hands, compared to its average volume of 1,481,486. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The firm has a market capitalization of $1.17 billion, a PE ratio of -54.33 and a beta of 1.22. The business has a fifty day moving average of $8.10 and a 200-day moving average of $7.86.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Invesco Ltd. lifted its stake in Aurinia Pharmaceuticals by 1.0% in the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company’s stock valued at $1,294,000 after buying an additional 1,421 shares during the period. Bridgefront Capital LLC lifted its stake in Aurinia Pharmaceuticals by 12.9% in the fourth quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,891 shares during the period. Cetera Investment Advisers lifted its stake in Aurinia Pharmaceuticals by 3.2% in the fourth quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company’s stock valued at $580,000 after buying an additional 2,000 shares during the period. Teacher Retirement System of Texas lifted its stake in Aurinia Pharmaceuticals by 5.9% in the fourth quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 2,020 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.